Evidence map›Paper›PMID 37931775›Full record

ReviewMutation research. Reviews in mutation research

Applications of advanced technologies for detecting genomic structural variation.

Vincent A Laufer, Thomas W Glover, Thomas E Wilson

Open access · greenAbstract readReview
In one paragraph

Review in Mutation research. Reviews in mutation research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Somatic mutations and genome mosaicism in aging and disease.Experimental & molecular medicine · 2026
    Review
  2. Article
  3. Detection of a complex chromosomal rearrangement in a novel mouse mutant by optical genome mapping.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Vincent A LauferDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: vlaufer@med.umich.edu.
Thomas W GloverDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: glover@med.umich.edu.
Thomas E WilsonDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: wilsonte@umich.edu.
University of Michigan · US

Funding

Cell cycle timing and molecular mechanisms of structural variant formation following incomplete replicationR01GM147026 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THOMAS W GLOVER, THOMAS EDWARD WILSON · 2023 to 2026
$2.0M
NIGMS NIH HHS R01 GM147026
6 · The paper itself

Abstract

Chromosomal structural variation (SV) encompasses a heterogenous class of genetic variants that exerts strong influences on human health and disease. Despite their importance, many structural variants (SVs) have remained poorly characterized at even a basic level, a discrepancy predicated upon the technical limitations of prior genomic assays. However, recent advances in genomic technology can identify and localize SVs accurately, opening new questions regarding SV risk factors and their impacts in humans. Here, we first define and classify human SVs and their generative mechanisms, highlighting characteristics leveraged by various SV assays. We next examine the first-ever gapless assembly of the human genome and the technical process of assembling it, which required third-generation sequencing technologies to resolve structurally complex loci. The new portions of that "telomere-to-telomere" and subsequent pangenome assemblies highlight aspects of SV biology likely to develop in the near-term. We consider the strengths and limitations of the most promising new SV technologies and when they or longstanding approaches are best suited to meeting salient goals in the study of human SV in population-scale genomics research, clinical, and public health contexts. It is a watershed time in our understanding of human SV when new approaches are expected to fundamentally change genomic applications.

Indexed as

GenomicsGenomic Structural VariationChromosome AberrationsGenome, HumanHumansSequence Analysis, DNACopy number variantCytogeneticsLong-read sequencingNext-generation sequencingStructural variantTechnology

Identifiers

PMID37931775
PMCPMC10792551
OpenAlexW4388342510

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.